Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | LTA4H | P09960 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.38 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28766354 | 0.84 | GABRA1 (0.35) | ALDH1A1MEN1KMT2ALMNAHPGD | |
| SCHEMBL13979698 | 0.79 | NAPRT (0.46) | NAPRTALDH1A1MEN1KMT2ACYP1A2 | |
| Benzene SCHEMBL27863753 | 0.78 | CES1 (0.44) | NAPRTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL13449660 | 0.78 | CES1 (0.44) | NAPRTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL13605887 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP3A4CYP2D6KDM4E | |
| SCHEMBL31077641 | 0.77 | KDM5C (0.45) | ALDH1A1KDM4E | |
| SCHEMBL29530928 | 0.77 | ALDH1A1 (0.53) | ALDH1A1CYP1A2CYP3A4CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL27818043 | 0.77 | CES1 (0.42) | NAPRTALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL16612045 | 0.75 | PARP10 (0.43) | ALDH1A1KMT2ACYP3A4CYP2C19LMNA | |
| SCHEMBL28827436 | 0.75 | CES2 (0.48) | MEN1KMT2ALTA4HHPGDPLOD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104334556-B | Novel sphingosine 1-phosphate receptor antagonists | 爱若优生物科技有限公司 | 2017-05-17 | — | — | CN | disclosed |
| US-8877935-B2 | One-pot process for the synthesis of dalfampridine | PROCOS S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| US-8877935-B2 | One-pot process for the synthesis of dalfampridine | PROCOS S.P.A. (IT) | 2014-11-04 | — | — | US | disclosed |
| EP-2394994-B1 | One-pot process for the synthesis of dalfampridine | PROCOS SPA (IT) | 2013-02-13 | — | — | EP | disclosed |
| US-20110319628-A1 | ONE-POT PROCESS FOR THE SYNTHESIS OF DALFAMPRIDINE | PROCOS S.P.A. (IT) | 2011-12-29 | — | — | US | disclosed |
| EP-2394994-A1 | One-pot process for the synthesis of dalfampridine | Procos S.p.A. (IT) | 2011-12-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319628-A1 | ONE-POT PROCESS FOR THE SYNTHESIS OF DALFAMPRIDINE | PFAS, FIP1L1, QDPR | NAPRT 732/4885ALDH1A1 792/4885MEN1 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.